Publications : 2022

Suh M, Cloud M, Balasubramanian A, Movva N, Fryzek J, Cohen S. 2022. A systematic literature review (SLR) of MTAP deletions in multiple solid and hematologic cancers. PROSPERO 2022 CRD42022354037.

Abstract

Review questions

  1. In the published literature, what are the reported frequencies of MTAP deletions among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, diffuse large B-cell lymphoma (DLBCL), or acute lymphoblastic leukemia (ALL) and among pediatric patients aged <18 years with ALL?
  2. In the published literature, what are the reported MTAP laboratory testing frequencies and types (protein expressions and genomic testing including next-generation sequencing [NGS]) among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, DLBCL, or ALL and among pediatric patients aged <18 years with ALL?
  3. In the published literature, what are the reported prognostic values such as survival and response (e.g., overall survival [OS], progression-free survival [PFS], objective response rate [ORR], resection rate [RR]) associated with MTAP deletions among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, DLBCL, or ALL and among pediatric patients aged <18 years with ALL?
  4. In the published literature, what are the reported associations between MTAP deletions and clinical, molecular, and sociodemographic factors among adult patients aged ≥18 years with cholangiocarcinoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, gallbladder carcinoma, glioblastoma, non-squamous cell lung cancer, mesothelioma, DLBCL, or ALL and among pediatric patients aged <18 years with ALL?